Table 2.
Clinical and questionnaire details for the asthma participants (N = 63) and healthy control participants (N = 30). Percentage of asthma or healthy control participants shown alongside absolute number. Variance is reported as mean ± standard deviation or median [interquartile range]. Asthma 'steps' as per definitions from the 2019 BTS/Sign guideline.
| Asthma | Healthy control | |||
|---|---|---|---|---|
| Age (years of age) | 44 ± 12 | 44 ± 12 | ||
| Gender (Female | Male) | 39 | 24 | 19 | 11 | ||
| BMI (kg/m2) | 27 ± 6 | 24 ± 3 | ||
| Peak Flow (L/min) | 435 ± 125 | 406 ± 108 | ||
| FeNO (ppb) | 29 ± 20 | 24 ± 18 | ||
| Eosinophil (× 109 cells/litre) | 0.13 ± 0.10 | 0.13 ± 0.12 | ||
| FEV1% predicted | 92 ± 26 | 101 ± 13 | ||
| Asthma "step" (median [IQR]) | 2 [1] | |||
| Number of participants "step 1" | 13 | |||
| Number of participants "step 2" | 25 | |||
| Number of participants "step 3" | 22 | |||
| Number of participants "step 4" | 3 | |||
| Number of participants "step 5" | 0 | |||
| Alcohol (units per week): | ||||
| 0 | 8 (13%) | 4 (13%) | ||
| 1–10 | 37 (59%) | 17 (57%) | ||
| 11–20 | 12 (19%) | 9 (30%) | ||
| > 20 | 4 (6%) | – | ||
| Number of hours asleep daily | ||||
| < 6 | 14 (22%) | 9 (30%) | ||
| > 6 | 48 (76%) | 21 (70%) | ||
| Asthma specific demographic information | ||||
| Age of asthma diagnosis (years of age) | ||||
| 0–10 | 29 (46%) | |||
| 11–20 | 11 (17%) | |||
| > 20 | 23 (37%) | |||
| Family history of asthma | ||||
| Yes | 27 (43%) | |||
| No | 34 (54%) | |||
| Number of asthma related adverse events | ||||
| 1 | 2 (3%) | |||
| Number of asthma related GP visits | ||||
| 0 | 22 (35%) | |||
| 1–5 | 37 (59%) | |||
| 6–10 | 4 (6%) | |||
| Number of asthma related hospital admissions | ||||
| 1 | 14 (22%) | |||
| Asthma triggers (number of participants in asthma group) | ||||
| Dust (40) (63%) | Exercise (39) (62%) | Pollen (34) (54%) | Smoke (28) (44%) | |
| Pets (26) (41%) | Stress (24) (38%) | Food (11) (17%) | ||
| Medication (number of participants in asthma group) | ||||
| Short-acting beta agonists (SABA) (59) (94%) | Long-acting beta agonists (LABA) (1) (2%) | |||
| Inhaled steroids (28) (44%) | Oral steroids (2) (3%) | |||
| Combined inhalers (steroid + LABA) (19) (30%) | Antimuscarinic inhaler (1) (2%) | |||
| Leukotriene receptor antagonist (3) (5%) | Antihistamines (6) (10%) | |||
| Antidepressants (6) (10%) | Diabetes medication (3) (5%) | |||
| Cardiovascular medications (7) (11%) | Antibiotics (2) (3%) | |||
| Antifungals (1) (2%) | Prescribed pain relief (1) (2%) | |||